Summit Therapeutics Inc. (SMMT) Stock
NASDAQ · SMMT
17.85
Fundamentals
Market cap
$14.24B
Price / Earnings ratio
-16.5x
Price / Sales ratio
N/A
Price / Book ratio
22.4x
Return on assets
-2.4%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Summit Therapeutics Inc.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
SectorHealthcare
IndustryBiotechnology
Employees265
CEOMr. Robert W. Duggan
IPO DateMar 5, 2015
HeadquartersMiami, FL
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert W. Duggan | Co-CEO & Executive Chairman | 1945 |
| Dr. Mahkam Zanganeh D.D.S., M.B.A. | Co-CEO, President & Director | 1970 |
| Mr. Manmeet Singh Soni CPA | COO, CFO & Director | 1978 |
| Prof. Kay Elizabeth Davies DBE, FRS CBE | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor | 1951 |
| Mr. Bhaskar Anand | Chief Accounting Officer & Head of Finance | 1978 |
| Mr. Nathan LiaBraaten | Senior Director of Investor Relations | — |
| Dr. Elaine Carla Stracker J.D., Ph.D. | Chief Legal Officer | 1961 |
| Mr. Dave Gancarz CPA | Chief Business & Strategy Officer | — |
| Dr. Wang Clow Fong ScD | Chief Biometrics Officer | 1958 |
| Dr. Urte Gayko Ph.D. | Chief Regulatory, Quality & Pharmacovigilance Officer | 1971 |
Fundamentals
Valuation
Market cap$14.24B
Price-to-sales ratioN/A
Price-to-book value22.44
Price-earnings ratio-16.50
Return on Equity-291.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratio0.00
Earnings Per Share
Earnings Per Share$-0.01
Income Statement
Average volume6,195,619
EBITDA$-1.21B
1 year high (52w)$29.23
1 year low (52w)$12.07
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



